U
16.36
1.18 (7.77%)
| Penutupan Terdahulu | 15.18 |
| Buka | 15.62 |
| Jumlah Dagangan | 1,348,728 |
| Purata Dagangan (3B) | 3,341,964 |
| Modal Pasaran | 1,022,981,184 |
| Harga / Pendapatan (P/E Ke hadapan) | 27.93 |
| Harga / Jualan (P/S) | 196.41 |
| Harga / Buku (P/B) | 2.83 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Operasi (TTM) | -2,815.25% |
| EPS Cair (TTM) | -4.38 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -81.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1,522.46% |
| Nisbah Semasa (MRQ) | 11.99 |
| Aliran Tunai Operasi (OCF TTM) | -166.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -122.89 M |
| Pulangan Atas Aset (ROA TTM) | -15.64% |
| Pulangan Atas Ekuiti (ROE TTM) | -241.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | uniQure N.V. | Menurun | Menaik |
AISkor Stockmoo
-0.1
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.13 |
|
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.09% |
| % Dimiliki oleh Institusi | 91.95% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 70.00 (HC Wainwright & Co., 327.87%) | Beli |
| Median | 33.00 (101.71%) | |
| Rendah | 9.00 (Cantor Fitzgerald, -44.99%) | Pegang |
| 9.00 (Goldman Sachs, -44.99%) | Pegang | |
| Purata | 35.00 (113.94%) | |
| Jumlah | 5 Beli, 3 Pegang | |
| Harga Purata @ Panggilan | 16.54 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Mizuho | 11 Mar 2026 | 35.00 (113.94%) | Beli | 17.56 |
| 03 Mar 2026 | 12.00 (-26.65%) | Pegang | 9.03 | |
| HC Wainwright & Co. | 10 Mar 2026 | 70.00 (327.87%) | Beli | 18.26 |
| 10 Feb 2026 | 70.00 (327.87%) | Beli | 24.71 | |
| Chardan Capital | 09 Mar 2026 | 31.00 (89.49%) | Beli | 17.99 |
| 03 Mar 2026 | 16.00 (-2.20%) | Beli | 9.03 | |
| RBC Capital | 09 Mar 2026 | 35.00 (113.94%) | Beli | 17.99 |
| Wells Fargo | 09 Mar 2026 | 60.00 (266.75%) | Beli | 17.99 |
| 03 Mar 2026 | 15.00 (-8.31%) | Pegang | 9.03 | |
| Goldman Sachs | 03 Mar 2026 | 9.00 (-44.99%) | Pegang | 9.03 |
| Cantor Fitzgerald | 02 Mar 2026 | 9.00 (-44.99%) | Pegang | 10.50 |
| Barclays | 28 Jan 2026 | 31.00 (89.49%) | Pegang | 23.02 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Mar 2026 | CNBC | FDA reversals leave investors worrying about the fates of other experimental drugs |
| 06 Mar 2026 | CNBC | FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease |
| 09 Jan 2026 | Pengumuman | uniQure Announces Type A Meeting Scheduled with FDA |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |